Vanderbilt University's Center for Neuroscience Drug Discovery continues to make progress on the business development front. In recent days, it has delivered preclinical compounds for fragile X disease to Seaside Therapeutics, selected three mGlu4 modulators for continued development in Parkinson's disease under a collaboration with the Michael J. Fox Foundation, and licensed a set of glycine transporter one inhibitors to Karuna Pharmaceuticals for development in schizophrenia.
A district court has entered a consent decree against Hill Dermaceuticals Inc. and Hill Labs Inc. prohibiting them from selling adulterated drugs. The government filed a complaint against the companies and against Hill's president and quality assurance manager alleging they violated current good manufacturing practices and submitted falsified data to FDA. The complaint also alleges the QA manager re-wrote notebooks covering testing from 2005-2010.
Denmark's Lundbeck A/S will invest £10.3 million ($16.1 million) in U.K.'s CNS-focused Proximagen Group PLC as part of a strategic partnership agreement announced Sept. 28. Lundbeck's support for Proximagen comes as biotechs struggle for survival in the high-risk CNS space
Ariel Pharmaceuticals has licensed three CNS products over the last nine months and plans to begin clinical trials next year. The biotech is also securing funding toward a Series A round of financing.
Merck CMO Michael Rosenblatt discussed Gardasil adverse events at a Galien Foundation forum in New York.
